Division of Allergy and Immunology, Department of Medicine, Washington University School of Medicine, St. Louis, United States
Madison Mack
Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States
Lydia Zamidar
Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, United States; Mark Lebwohl Center for Neuroinflammation and Sensation, Icahn School of Medicine at Mount Sinai, New York, United States; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, United States; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, United States
Masato Tamari
Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, United States; Mark Lebwohl Center for Neuroinflammation and Sensation, Icahn School of Medicine at Mount Sinai, New York, United States; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, United States; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, United States
Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, United States
Anna M Trier
Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, United States
Do-Hyun Kim
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, United States; Department of Life Science, College of Natural Sciences, Hanyang University, Seoul, Republic of Korea
Hannah Janzen-Meza
Division of Allergy and Immunology, Department of Medicine, Washington University School of Medicine, St. Louis, United States
Steven J Van Dyken
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, United States
Chyi-Song Hsieh
Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, United States
Jenny M Karo
Immunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medical College, New York, United States; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, United States
Joseph C Sun
Immunology and Microbial Pathogenesis Program, Graduate School of Medical Sciences, Weill Cornell Medical College, New York, United States; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, United States
Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, United States; Mark Lebwohl Center for Neuroinflammation and Sensation, Icahn School of Medicine at Mount Sinai, New York, United States; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, United States; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, United States; Allen Discovery Center for Neuroimmune Interactions, Icahn School of Medicine at Mount Sinai, New York, United States
Antigen specificity is the central trait distinguishing adaptive from innate immune function. Assembly of antigen-specific T cell and B cell receptors occurs through V(D)J recombination mediated by the Recombinase Activating Gene endonucleases RAG1 and RAG2 (collectively called RAG). In the absence of RAG, mature T and B cells do not develop and thus RAG is critically associated with adaptive immune function. In addition to adaptive T helper 2 (Th2) cells, group 2 innate lymphoid cells (ILC2s) contribute to type 2 immune responses by producing cytokines like Interleukin-5 (IL-5) and IL-13. Although it has been reported that RAG expression modulates the function of innate natural killer (NK) cells, whether other innate immune cells such as ILC2s are affected by RAG remains unclear. We find that in RAG-deficient mice, ILC2 populations expand and produce increased IL-5 and IL-13 at steady state and contribute to increased inflammation in atopic dermatitis (AD)-like disease. Furthermore, we show that RAG modulates ILC2 function in a cell-intrinsic manner independent of the absence or presence of adaptive T and B lymphocytes. Lastly, employing multiomic single cell analyses of RAG1 lineage-traced cells, we identify key transcriptional and epigenomic ILC2 functional programs that are suppressed by a history of RAG expression. Collectively, our data reveal a novel role for RAG in modulating innate type 2 immunity through suppression of ILC2s.